{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:10:56Z","timestamp":1789031456088,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014791","name":"University of Sk\u00f6vde","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014791","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Drug repurposing has emerged as an attractive strategy in contemporary pharmaceutical research, presenting an opportunity to expedite drug discovery, minimize developmental costs, and mitigate risks associated with developing new pharmaceuticals. In this study, we investigated a novel approach based on deep learning of human transcriptomic mechanisms for systematic identification of additional therapeutic potential in preexisting drugs. We trained a composite feedforward neural network model using gene expression data sourced from the ARCHS4 compilation of the GEO, encompassing extensive human datasets. Subsequently, disease-associated gene expression data were generated from our stem cell-derived\n                    <jats:italic>in vitro<\/jats:italic>\n                    model of cardiac hypertrophy induced by Endothelin-1 stimulation. These data were employed to identify latent variables associated with genes showing differential expression due to Endothelin-1 stimulation. By examining the differential expression profiles within the model's latent space, we successfully correlated the disease signal with known drug targets found in pharmaceutical compounds cataloged in DrugBank. The model accurately encoded additional disease-related genes beyond the curated gene set, demonstrating its ability to generalize disease associations. Leveraging the model, we identified potential drug candidates, such as lapatinib and amiodarone showing promise in mitigating proBNP concentration associated with cardiac hypertrophy. This study demonstrates the power of deep learning of human transcriptomic mechanisms in swiftly identifying new therapeutic potentials for existing drugs, highlighting the pivotal role of artificial intelligence technologies in accelerating drug development for other complex medical conditions.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-68286-z","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:45:45Z","timestamp":1789029945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging neural network models for drug repurposing: a case study on cardiac hypertrophy"],"prefix":"10.1038","volume":"16","author":[{"given":"Rasmus","family":"Magnusson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Hagvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-0590","authenticated-orcid":false,"given":"Jane","family":"Synnergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"1","key":"68286_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13063-021-05273-x","volume":"22","author":"C Verbaanderd","year":"2021","unstructured":"Verbaanderd, C., Rooman, I. & Huys, I. Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research. Trials22(1), 322 (2021).","journal-title":"Trials"},{"key":"68286_CR2","doi-asserted-by":"publisher","first-page":"1460100","DOI":"10.3389\/fddsv.2024.1460100","volume":"4","author":"P Luca","year":"2024","unstructured":"Luca, P., Bisi, N. & Giulio, R. How drug repurposing can advance drug discovery: challenges and opportunities. Front. Drug Discov.4, 1460100 (2024).","journal-title":"Front. Drug Discov."},{"issue":"8","key":"68286_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov.3(8), 673\u201383 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"68286_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello, S. M. et al. The drug repurposing hub: a next-generation drug library and information resource. Nat. Med.23(4), 405\u2013408 (2017).","journal-title":"Nat. Med."},{"issue":"4","key":"68286_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","volume":"14","author":"TI Oprea","year":"2012","unstructured":"Oprea, T. I. & Mestres, J. Drug repurposing: far beyond new targets for old drugs. AAPS J.14(4), 759\u201363 (2012).","journal-title":"AAPS J."},{"issue":"1","key":"68286_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov.18(1), 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68286_CR7","doi-asserted-by":"publisher","first-page":"1028545","DOI":"10.3389\/fpubh.2022.1028545","volume":"10","author":"CCY Chung","year":"2022","unstructured":"Chung, C. C. Y. et al. Rare disease emerging as a global public health priority. Front. Health Policy10, 1028545 (2022).","journal-title":"Front. Health Policy"},{"key":"68286_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.pmbts.2024.03.030","volume":"205","author":"SK Ghandikota","year":"2024","unstructured":"Ghandikota, S. K. & Jegga, A. G. Application of artificial intelligence and machine learning in drug repurposing. Prog. Mol. Biol. Transl. Sci.205, 171\u2013211 (2024).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"1","key":"68286_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13054-022-04205-8","volume":"27","author":"M Troseid","year":"2023","unstructured":"Troseid, M. et al. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Crit. Care27(1), 9 (2023).","journal-title":"Crit. Care"},{"issue":"10","key":"68286_CR10","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","volume":"24","author":"V Parvathaneni","year":"2019","unstructured":"Parvathaneni, V. et al. Drug repurposing: A promising tool to accelerate the drug discovery process. Drug Discov. Today24(10), 2076\u20132085 (2019).","journal-title":"Drug Discov. Today"},{"issue":"5","key":"68286_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","volume":"19","author":"G Jin","year":"2014","unstructured":"Jin, G. & Wong, S. T. Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today19(5), 637\u201344 (2014).","journal-title":"Drug Discov. Today"},{"issue":"16","key":"68286_CR12","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1093\/bioinformatics\/bty133","volume":"34","author":"A Peyvandipour","year":"2018","unstructured":"Peyvandipour, A. et al. A novel computational approach for drug repurposing using systems biology. Bioinformatics34(16), 2817\u20132825 (2018).","journal-title":"Bioinformatics"},{"issue":"19","key":"68286_CR13","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/bioinformatics\/btz156","volume":"35","author":"N Saberian","year":"2019","unstructured":"Saberian, N. et al. A new computational drug repurposing method using established disease-drug pair knowledge. Bioinformatics35(19), 3672\u20133678 (2019).","journal-title":"Bioinformatics"},{"key":"68286_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-4939-8955-3_9","volume":"1903","author":"E Karatzas","year":"2019","unstructured":"Karatzas, E., Kolios, G. & Spyrou, G. M. An application of computational drug repurposing based on transcriptomic signatures. Methods Mol. Biol.1903, 149\u2013177 (2019).","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"68286_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34277-7","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data. Nat. Commun.13(1), 6494 (2022).","journal-title":"Nat. Commun."},{"issue":"5","key":"68286_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","volume":"38","author":"BM Kuenzi","year":"2020","unstructured":"Kuenzi, B. M. et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell38(5), 672-684 e6 (2020).","journal-title":"Cancer Cell"},{"issue":"D1","key":"68286_CR17","first-page":"D845","volume":"48","author":"J Pinero","year":"2020","unstructured":"Pinero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res.48(D1), D845\u2013D855 (2020).","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"68286_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1161\/01.CIR.0000120390.68287.BB","volume":"109","author":"N Frey","year":"2004","unstructured":"Frey, N. et al. Hypertrophy of the heart: a new therapeutic target?. Circulation109(13), 1580\u20139 (2004).","journal-title":"Circulation"},{"issue":"9","key":"68286_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s42255-020-0262-1","volume":"2","author":"JBN Moreira","year":"2020","unstructured":"Moreira, J. B. N., Wohlwend, M. & Wisloff, U. Exercise and cardiac health: physiological and molecular insights. Nat. Metab.2(9), 829\u2013839 (2020).","journal-title":"Nat. Metab."},{"issue":"11","key":"68286_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1161\/01.RES.0000170652.71414.16","volume":"96","author":"M Eghbali","year":"2005","unstructured":"Eghbali, M. et al. Molecular and functional signature of heart hypertrophy during pregnancy. Circ. Res.96(11), 1208\u201316 (2005).","journal-title":"Circ. Res."},{"issue":"9","key":"68286_CR21","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham, Y. K. et al. Pathophysiology of cardiac hypertrophy and heart failure: Signaling pathways and novel therapeutic targets. Arch. Toxicol.89(9), 1401\u201338 (2015).","journal-title":"Arch. Toxicol."},{"issue":"2","key":"68286_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.119.040332","volume":"141","author":"M Hieda","year":"2020","unstructured":"Hieda, M. et al. Increased myocardial stiffness in patients with high-risk left ventricular hypertrophy: The hallmark of stage-B heart failure with preserved ejection fraction. Circulation141(2), 115\u2013123 (2020).","journal-title":"Circulation"},{"key":"68286_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","volume":"65","author":"N Frey","year":"2003","unstructured":"Frey, N. & Olson, E. N. Cardiac hypertrophy: The good, the bad, and the ugly. Annu. Rev. Physiol.65, 45\u201379 (2003).","journal-title":"Annu. Rev. Physiol."},{"issue":"13","key":"68286_CR24","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1056\/NEJMra072139","volume":"358","author":"JA Hill","year":"2008","unstructured":"Hill, J. A. & Olson, E. N. Cardiac plasticity. N. Engl. J. Med.358(13), 1370\u201380 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"68286_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol.15(7), 387\u2013407 (2018).","journal-title":"Nat. Rev. Cardiol."},{"issue":"Suppl A","key":"68286_CR26","doi-asserted-by":"publisher","first-page":"A13","DOI":"10.1253\/circj.CJ-08-0481","volume":"72","author":"T Oka","year":"2008","unstructured":"Oka, T. & Komuro, I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ. J.72(Suppl A), A13-6 (2008).","journal-title":"Circ. J."},{"issue":"5","key":"68286_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41569-022-00806-6","volume":"20","author":"TG Martin","year":"2023","unstructured":"Martin, T. G., Juarros, M. A. & Leinwand, L. A. Regression of cardiac hypertrophy in health and disease: Mechanisms and therapeutic potential. Nat. Rev. Cardiol.20(5), 347\u2013363 (2023).","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"68286_CR28","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41467-018-03751-6","volume":"9","author":"A Lachmann","year":"2018","unstructured":"Lachmann, A. et al. Massive mining of publicly available RNA-seq data from human and mouse. Nat. Commun.9(1), 1366 (2018).","journal-title":"Nat. Commun."},{"issue":"11","key":"68286_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2024.101093","volume":"5","author":"HA de Weerd","year":"2024","unstructured":"de Weerd, H. A. et al. Latent space arithmetic on data embeddings from healthy multi-tissue human RNA-seq decodes disease modules. Patterns5(11), 101093 (2024).","journal-title":"Patterns"},{"key":"68286_CR30","unstructured":"Kingma, D.P. and J. Ba, Adam: A method for stochastic optimization.arXiv:1412.6980v9 [cs.LG] (2017)."},{"key":"68286_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/life12020293","author":"M Johansson","year":"2022","unstructured":"Johansson, M. et al. Multi-omics characterization of a human stem cell-based model of cardiac hypertrophy. Lifehttps:\/\/doi.org\/10.3390\/life12020293 (2022).","journal-title":"Life"},{"key":"68286_CR32","doi-asserted-by":"publisher","first-page":"10331","DOI":"10.1038\/ncomms10331","volume":"7","author":"E Guney","year":"2016","unstructured":"Guney, E. et al. Network-based in silico drug efficacy screening. Nat. Commun.7, 10331 (2016).","journal-title":"Nat. Commun."},{"issue":"4","key":"68286_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer, A. et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics30(4), 523\u201330 (2014).","journal-title":"Bioinformatics"},{"issue":"1","key":"68286_CR34","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/s41467-020-14666-6","volume":"11","author":"SK Dwivedi","year":"2020","unstructured":"Dwivedi, S. K. et al. Deriving disease modules from the compressed transcriptional space embedded in a deep autoencoder. Nat. Commun.11(1), 856 (2020).","journal-title":"Nat. Commun."},{"issue":"1","key":"68286_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41540-022-00218-9","volume":"8","author":"R Magnusson","year":"2022","unstructured":"Magnusson, R., Tegner, J. N. & Gustafsson, M. Deep neural network prediction of genome-wide transcriptome signatures - Beyond the black-box. NPJ Syst. Biol. Appl.8(1), 9 (2022).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"68286_CR36","doi-asserted-by":"publisher","unstructured":"de Weerd, H.A., et al., Representational learning from healthy multi-tissue human RNA-seq data such that latent space arithmetics extracts disease modules.https:\/\/www.biorxiv.org\/content\/https:\/\/doi.org\/10.1101\/2023.10.03.560661v1 (2024).","DOI":"10.1101\/2023.10.03.560661v1"},{"issue":"9","key":"68286_CR37","doi-asserted-by":"publisher","first-page":"bio052381","DOI":"10.1242\/bio.052381","volume":"9","author":"M Johansson","year":"2020","unstructured":"Johansson, M. et al. Cardiac hypertrophy in a dish: a human stem cell based model. Biol. Open9(9), bio052381 (2020).","journal-title":"Biol. Open"},{"key":"68286_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2025.09.025","volume":"587","author":"W Bao","year":"2025","unstructured":"Bao, W. et al. DJ-1\/PARK7 in Parkinson\u2019s disease: Mechanisms of pathogenesis and therapeutic potential. Neuroscience587, 1\u201313 (2025).","journal-title":"Neuroscience"},{"issue":"15","key":"68286_CR39","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1073\/pnas.1303444110","volume":"110","author":"F Billia","year":"2013","unstructured":"Billia, F. et al. Parkinson-susceptibility gene DJ-1\/PARK7 protects the murine heart from oxidative damage in vivo. Proc. Natl. Acad. Sci. U. S. A.110(15), 6085\u201390 (2013).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"68286_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413488","author":"L Cuenca-Bermejo","year":"2021","unstructured":"Cuenca-Bermejo, L. et al. Cardiac changes in Parkinson\u2019s disease: Lessons from clinical and experimental evidence. Int. J. Mol. Sci.https:\/\/doi.org\/10.3390\/ijms222413488 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"68286_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612601","author":"B Lee","year":"2023","unstructured":"Lee, B. et al. Clinical and non-clinical cardiovascular disease associated pathologies in Parkinson\u2019s disease. Int. J. Mol. Sci.https:\/\/doi.org\/10.3390\/ijms241612601 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"68286_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/01616412.2017.1390933","volume":"40","author":"J Piqueras-Flores","year":"2018","unstructured":"Piqueras-Flores, J. et al. Structural and functional alterations of the heart in Parkinson\u2019s disease. Neurol. Res.40(1), 53\u201361 (2018).","journal-title":"Neurol. Res."},{"issue":"1","key":"68286_CR43","doi-asserted-by":"publisher","first-page":"19955","DOI":"10.1038\/s41598-022-24421-0","volume":"12","author":"E Qumsiyeh","year":"2022","unstructured":"Qumsiyeh, E., Showe, L. & Yousef, M. GediNET for discovering gene associations across diseases using knowledge based machine learning approach. Sci. Rep.12(1), 19955 (2022).","journal-title":"Sci. Rep."},{"key":"68286_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2018.04.031","volume":"53","author":"FA Scorza","year":"2018","unstructured":"Scorza, F. A. et al. Cardiac abnormalities in Parkinson\u2019s disease and Parkinsonism. J. Clin. Neurosci.53, 1\u20135 (2018).","journal-title":"J. Clin. Neurosci."},{"key":"68286_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040296","author":"LD Skou","year":"2024","unstructured":"Skou, L. D. et al. Pathogenesis of DJ-1\/PARK7-mediated Parkinson\u2019s disease. Cellshttps:\/\/doi.org\/10.3390\/cells13040296 (2024).","journal-title":"Cells"},{"issue":"10","key":"68286_CR46","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.jacc.2003.07.009","volume":"42","author":"U Hink","year":"2003","unstructured":"Hink, U. et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J. Am. Coll. Cardiol.42(10), 1826\u201334 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"68286_CR47","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0002-9149(98)00006-X","volume":"81","author":"CM Pratt","year":"1998","unstructured":"Pratt, C. M. et al. Mortality in the survival With ORal D-sotalol (SWORD) trial: why did patients die?. Am. J. Cardiol.81(7), 869\u201376 (1998).","journal-title":"Am. J. Cardiol."},{"key":"68286_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/life12050726","author":"M Johansson","year":"2022","unstructured":"Johansson, M. et al. Data mining identifies CCN2 and THBS1 as biomarker candidates for cardiac hypertrophy. Lifehttps:\/\/doi.org\/10.3390\/life12050726 (2022).","journal-title":"Life"},{"key":"68286_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ.47, 20\u201333 (2016).","journal-title":"J. Health Econ."},{"issue":"3","key":"68286_CR50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/clpt.2009.293","volume":"87","author":"KI Kaitin","year":"2010","unstructured":"Kaitin, K. I. Deconstructing the drug development process: The new face of innovation. Clin. Pharmacol. Ther.87(3), 356\u201361 (2010).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"68286_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/d41573-020-00001-7","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. 2019 FDA drug approvals. Nat. Rev. Drug Discov.19(2), 79\u201384 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"68286_CR52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nrd3405","volume":"10","author":"F Pammolli","year":"2011","unstructured":"Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov.10(6), 428\u201338 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68286_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.06.012","author":"A Neuberger","year":"2018","unstructured":"Neuberger, A., Oraiopoulos, N. & Drakeman, D. L. Renovation as innovation: Is repurposing the future of drug discovery research. Drug Discov. Todayhttps:\/\/doi.org\/10.1016\/j.drudis.2018.06.012 (2018).","journal-title":"Drug Discov. Today"},{"key":"68286_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1912733","author":"C Gil","year":"2021","unstructured":"Gil, C. & Martinez, A. Is drug repurposing really the future of drug discovery or is new innovation truly the way forward. Expert Opin. Drug Discov.https:\/\/doi.org\/10.1080\/17460441.2021.1912733 (2021).","journal-title":"Expert Opin. Drug Discov."},{"issue":"11","key":"68286_CR55","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","volume":"39","author":"M Schlander","year":"2021","unstructured":"Schlander, M. et al. How much does it cost to research and develop a new drug? a systematic review and assessment. Pharmacoeconomics39(11), 1243\u20131269 (2021).","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"68286_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1055\/a-2095-0826","volume":"73","author":"S Kumar","year":"2023","unstructured":"Kumar, S. & Roy, V. Repurposing drugs: an empowering approach to drug discovery and development. Drug Res (Stuttg)73(9), 481\u2013490 (2023).","journal-title":"Drug Res (Stuttg)"},{"issue":"9","key":"68286_CR57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2009","unstructured":"Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA323(9), 844\u2013853 (2009).","journal-title":"JAMA"},{"issue":"6","key":"68286_CR58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40256-020-00401-5","volume":"20","author":"D Hamilton Sr.","year":"2020","unstructured":"Hamilton, D. Sr. et al. Amiodarone: a comprehensive guide for clinicians. Am. J. Cardiovasc. Drugs20(6), 549\u2013558 (2020).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"68286_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume":"211","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender, M., Schneider-Merck, T. & Trepel, M. Lapatinib. Recent Results Cancer Res.211, 19\u201344 (2018).","journal-title":"Recent Results Cancer Res."},{"issue":"14","key":"68286_CR60","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2174\/092986706777441968","volume":"13","author":"FL Marasciulo","year":"2006","unstructured":"Marasciulo, F. L., Montagnani, M. & Potenza, M. A. Endothelin-1: The yin and yang on vascular function. Curr. Med. Chem.13(14), 1655\u201365 (2006).","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"68286_CR61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s002100000264","volume":"362","author":"C Martin","year":"2000","unstructured":"Martin, C., Held, H. D. & Uhlig, S. Differential effects of the mixed ET(A)\/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release. Naunyn Schmiedebergs Arch. Pharmacol.362(2), 128\u201336 (2000).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"68286_CR62","unstructured":"Kingma, D.P. and M. Welling, Auto-encoding variational bayes, in In 2nd International Conference on Learning Representations (ICLR) April 14-16 Banff, AB, Canada (2014)."},{"key":"68286_CR63","doi-asserted-by":"crossref","unstructured":"Ribeiro, M.T., S. Singh, and C. Guestrin, \u201cWhy should i trust you?\u201d explaining the predictions of any classifier. KDD '16 proceedings (ACM SIGKDD, pp. 1135\u20131144).","DOI":"10.1145\/2939672.2939778"},{"issue":"32","key":"68286_CR64","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","volume":"34","author":"CJ Coats","year":"2013","unstructured":"Coats, C. J. et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur. Heart J.34(32), 2529\u201337 (2013).","journal-title":"Eur. Heart J."},{"issue":"42","key":"68286_CR65","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1093\/eurheartj\/ehae590","volume":"45","author":"CJ Coats","year":"2024","unstructured":"Coats, C. J. et al. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Euro. Heart J.45(42), 4464\u20134478 (2024).","journal-title":"Euro. Heart J."},{"issue":"9","key":"68286_CR66","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1157\/13125520","volume":"61","author":"P Morillas","year":"2008","unstructured":"Morillas, P. et al. Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. a cardiac magnetic resonance study. Rev. Esp. Cardiol.61(9), 972\u20135 (2008).","journal-title":"Rev. Esp. Cardiol."},{"issue":"2","key":"68286_CR67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijcard.2003.07.019","volume":"96","author":"JM Rivera Otero","year":"2004","unstructured":"Rivera Otero, J. M. et al. Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. Int. J. Cardiol.96(2), 265\u201371 (2004).","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"68286_CR68","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.bbadis.2013.07.003","volume":"1832","author":"IA Sergeeva","year":"2013","unstructured":"Sergeeva, I. A. & Christoffels, V. M. Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim. Biophys. Acta1832(12), 2403\u201313 (2013).","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68286-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:57:53Z","timestamp":1789030673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68286-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68286"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-68286-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sepideh Hagvall is employed at AstraZeneca. All the other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28333"}}